2 1 Shi Ji Jing Ji Bao Dao·2025-06-16 08:13Core Insights - The article discusses how financial institutions, particularly CITIC Bank, are supporting hard technology companies in overcoming challenges related to high R&D costs and long industrialization cycles through innovative financial products like "Technology Achievement Transformation Loan" [1][2] Group 1: Hard Technology Companies - Xinhuachu, established in 2023, focuses on zinc-nickel flow battery technology, which has been in development since 2015 and has achieved small-scale production after 8 years of research [1][2] - The unique advantages of Xinhuachu's technology include safety and environmental friendliness, addressing the bottleneck of distributed photovoltaic grid consumption, which is currently only 15% in rural areas of China [1][2] - The company has developed a solution that connects transformers and energy storage devices, significantly improving grid consumption capacity from 15% to 50%, tripling the original capacity [2] Group 2: Financial Support and Collaboration - CITIC Bank provided initial credit support during Xinhuachu's angel investment stage, customizing financial service solutions based on technology sources, patent numbers, and key project involvement [2][4] - The bank's "1+2 approval" fast track significantly enhances approval efficiency, alleviating pressure on the company's pilot base upgrades and equipment procurement [2] - CITIC Bank's comprehensive financial services, including bond issuance and asset securitization, are crucial for the growth of companies like Xinhuachu [2] Group 3: Other Hard Technology Innovations - Huashinuo, founded in 2018, specializes in precision ophthalmology and targeted drug development, with several international patents and national research project endorsements [3] - The company has developed innovative medical devices, including a single-use anterior chamber puncture device, aimed at improving precision diagnostics in county-level hospitals [3] - Huashinuo's breakthrough in drug delivery technology has entered clinical trials and has received patents in major global markets, showcasing its potential for treating eye diseases [3][4]